Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access

MBOT 12.10.2024

Full Press ReleaseSEC FilingsOur MBOT Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
  • 01.13.2025 - Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
  • 01.10.2025 - Microbot Medical Closes $8.6 Million Registered Direct Offering

Recent Filings

  • 01.22.2025 - D Notice of Exempt Offering of Securities
  • 01.21.2025 - 8-K Current report
  • 01.21.2025 - EX-99.1 EX-99.1

Livestream Interview Can be Viewed Today at10:50am ETatBenzinga All Access Live

BRAINTREE, Mass.,Dec. 10, 2024(GLOBE NEWSWIRE) --Microbot Medical®Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY®Endovascular Robotic System, announces that its Chief Executive Officer,Harel Gadot, will be interviewed on Benzinga All Access at10:50am ETonDecember 10, 2024. The live interview can be viewed at:Benzinga All Access Live.Mr. Gadotwill discuss Microbot Medical’s LIBERTY system, the continued growth and adoption of surgical robotics, and how the Company plans to redefine the peripheral endovascular space with LIBERTY®.

Earlier today, the Company announced that it has submitted the FDA 510(k) for commercialization of the LIBERTY® Endovascular Robotic System.

As the world’s first single-use, fully disposable endovascular robotic system, LIBERTY®eliminates the need for large and expensive capital equipment and streamlines customers’ access to robotics. With its remote control, LIBERTY®is designed to significantly reduce radiation exposure to physicians and staff, and improve ergonomics, which has the potential to reduce the physical strain on healthcare providers. The Company also believes that LIBERTY®has the potential to lower procedure costs, increase procedure efficiency and improve the overall quality of care.

AboutMicrobot Medical®Microbot Medical®Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.

Further information aboutMicrobot Medical®is available athttp://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities forMicrobot Medical®Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY®Endovascular Robotic Surgical System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY®Endovascular Robotic Surgical System inthe United States, disruptions resulting from new and ongoing hostilities betweenIsraeland the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facingMicrobot Medical®can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with theSecurities and Exchange Commission(SEC), which are available on the SEC’s web site atwww.sec.gov.Microbot Medical®disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:IR@microbotmedical.com

Primary Logo

Source: Microbot Medical Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com